Carmoxirole, a novel selective DA2-receptor agonist, acutely reduces neurohormonal activation and improves cardiac function in moderate to severe heart failure  by van der Ent, Martin et al.
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We corctude that cardiac cacbexta is chamctarised by a marked absolute 
bone loss and a reduction of bone der~ily, possibly taadlng to increased 
fracture risk. Taking % Ideal body weight as a measure of atrophy, humora! 
catabolic factors such as TNF-a and cortisol (and possibly ethere) contribute 
partly to reduced bone mineral density. 
~ '~- -~ Vitsmin O Deficiency Is Common in Heart Failure 
Donna Mmctnt, Kefih Aareneon, Ann Foray, vicki A(~lresso, Stuart Katz, 
Elizabeth Shone. Columbia-Prebyterian Medical Center, NY, IVY 
Calcitrol (CT), the active matsbollte of Vitamin D 0tit 13) produced by the 
kidney, regulates plasma calcium (Ca) by its actions at bone, kidney end 
intestine. Recently other actions of CT have been described including rapid, 
non-genomlo activation of Ca channels in "nontmditionat" tissues. In vascular 
smco~ muscle, CT incr_~sen ~cell g ro~ and the contractile respo,-.~e to 
noreptnephfine, tn the heart, low CT has been associated with impaired 
mitochreoddal oxidative posphorylation, decreased contrantilily, and increase 
hypertrophy. V'it D status can be assessed by meast, dng soum CT or Calcidiol 
(CD, the storage form of Vit D). To evaluate Vii D status in CHF, serum CT, 
CD, parathyroid hormone (PTH), Ca, PO4, BUN, crealinine (Cr), 24 hr udnary 
Ca and Cr were measured in 84 patients. Hemedynamlo measurements, 
LVEF, peak VO2, pdodty status at transplant were also measured. The 11 
patlonts with low CD levels were more likely to be Status I (13 < 0.02), 
had lower peak VO2 (12.5 :E 3.7 vs 7.4 ± 4.9 ml/kg]mfn;p < 0.05), lower 
serum Ca (9,6 :E 0.1 vs 8.8 • 0.2 mg/dl; p < 0,001) and tendency to 
higher mean pulmonary artery pressures, The 22 patients with low CT levels 
had a significant reduction in crealinine clearance (60 :E 21 vs 39 :l: 22 
ml/min;p < 0.00!) and serum Ca (9,6 -4- 0.1 vs 9.3 :E 0.2; p < 0.05). Only 
4 paUents had Significantly reduced CD and CT levels. High PTH levels 
(> 65 pg/ml), present in 25 patients, did not correlate with renal function 
or Vii D levels. LVEF was s'~gar in low Vit D and high PTH groups, lo 
conclusion, Vit D deficiency is a common finding in patients with CHE CD 
deficiency correlates with the severity of the disease and is probably related 
to combination of dietary factors, malabsorption and low sunlight exposure. 
CT deficiency is closely associated with renal insufficiency. Though major 
hemodynemie differences were not found between ormal and Vit 13 deficient 
patients, further investigstion is warranted to determine if Vit D administration 
has therapeutic benefit in this patient population. 
~"~ High Circulating Levels of  Cardiac Tfoponin I in 
Human Congeative Heart Failure 
Emile Missov, Chadas Calzolari 1 Bernard Pau 2. Department of Cardiology, 
Ueiversity Hospital, Montpellier, France; 1 Sanofi Recherche, Montpeltier, 
France; 2 CNRS UMR 9921, Montt~llier, France 
Neuro-endecdne and immune dysfunction have been extensively reported in 
congestive heart failure (CHF) patients, However, the biochemical diagnosis 
of CHF lacks specificity. Cardiac troponin I (cTnl) is a regulatory protein 
uniquely located in the myocardium with 31 additional amino acid residues 
at the N-terminal and more than 40% dissimilarity with the skeletal muscle 
Isoforms. in the present study, we postulated that end-stage CHF patients 
would have high cimutating levels of cTnl. Sere from 11 male end-stage CHF 
ps~isnts (mean age 46 :t: 11 years, mean LV ejection fraction 19.3 :E 5.9%), 
and from 11 healthy control subjects were assessed for cTnt using a highly 
specific slngis-alep immunoenzymomaldc assay without crossreactivity with 
the skeletal muscle isoforms (cut-off value 10 pg/mL, detection limit 3 pg/mL), 
High circulating levels of cTnt were found In all but one CHF patients. The 
median (25th, 75th percentile) serum cTni was 32 (15, 55) pg/mL, mean (SD) 
89 (166) WmL in CHF patients and belOw the detection limit of the assay 
in control subjects 0 (0, 5) pg/mL, mean (SD.) 2.9 (3.8) pg/mL, p = 0.gg0t. 
Furthermore, oTnl was strongly associated with LV eje~on fraction in CHF 
patients (R = -0.70, p = 0.01): the higher the cTnl levels, the lower the 
ejection fraction. This study provides the first evidence for elevated serum 
cTnl in human end-ctage CHF. cTn[ is a reliable cardiac-specific marker 
molecule that could be used for screening and risk-assessment in CHF 
patients. 
~- '~ Evaluation of  Magnitude of  Effect and Si,t;e of  
Action of Oopamine on the Renal Circula,~ion in 
Patients With Heart Fellure With the Aid of 
Intravescuiar Ultrasound and Doppler Techniquee 
Ud Elkeyam, Sameh Gedallah, Anilkumar Mehra, Rejendra Vallabhaneni, 
Janet V. Johnson. USC SchoM o/ Medicine, Los Angeles, CA 
Although "renal dose* dopamine is often used to increeso renal blood flow 
(RBF), data on magnitude of effect and sits of action are scarce. We evaluated 
the renal effect of intravenous dopamlne in doses of 1, 2, 3, 5 and 10 
mcg/kg/mln in 11 pts with chronic heart failure (CHF) undergoing cardiac 
catheterization. Effect on mean renal artedat pressure (RAP), renal artery 
cross sectional area (CSA), renal vascular resistance (RVR) and F'=JF were 
assessed. CSA was measured by intravascular ultrasound and renal artery 
flow velocity by intravascular Doppler, The effects were as follows: 
FlAP CSA RVR RBF 
(mmHg) (cm 2) (dynes) (ml/min) 
Baseline 95 ± 5 0.256 :E 0.02 16243 ±1861 475 ± 64 
1 mcg~min 93:~5 0.268 ~: 0.02 13248 ±t796" 608±98 
2 mcg/kg/m|n 93±6 0.285 • 0.02 11785±1728" 711:~141 
3 mcg/kg/mtn 96 :t: 5 0.290 ± 0.02 10218 =t: 1362" 74e :E 70* 
5 mcg/kg/mln 100 ± 4 0.299 ~: 0.02 9359 .+. 1385* 8764- 99' 
10 mcg/kg/mln 1024-11 0,268 d: 0.0A 10014±1996' 765:1:133" 
• p < 0.05 vs baseline 
Conclusions: 1) Dopamlne at 3-10 mng]kg/min results in a significant 
augmentstion of RBF in pts with CHF with a maximum effect of 108 :E 30% 
at 8 mcg/kg/min; 2) marked increase in RBF in spite of only a small and 
statistically insignificant increase in CSA suggest dilation of renal resistance 
vessels as a predominant site of dopamine effect on the renal circulation, 
~ Cacmoxirole, a Novel Selective DAe-Receptor 
Agoniat, Acutely Reduces Neurohormonal  
Activation and Improves Cardiac Function in 
Moderate to Severe Heart Failure 
Martin van der Ent, Ad F.M. van den Heuvel, Wlitem J. Remme. Sticares 
Foundation, Rotterdam, The Nethedands 
In heart failure therapy, one of the novel approaches concerns further modu- 
lation of neurohormonal ctivation in addition to ACE inhibition. EMD 45609 
(carmoxireta, C), a DAe-recepter agonist with limited central activity, modu- 
lates sympathetic activation and subsequently reduces pro- and afterloed. 
As the effect of a specific DAe-agnnist has not been studied yet in heart 
failure patients, the effect of C on neumhermones and hemodynamics was 
evaluated in 12 normotsnsive patients with NYHA cl Ill-IV heart failure on sta- 
ble ACE-inhibitor and diuretic therapy. C (0.25-1.00 rag) was administered 
on 2 consecutive days, and hemodynamio and neumhormunal measure- 
men~ carded out, Values given am maximal % changes ,'ram baseline (p 
< 0.05). The lower dose on day I (0.25-0.50 rag) reduced circulating nore- 
pinephdne, vesOpressin and ANF by 40%, 19°/,, and 25%, rasp. In addition, 
on day 2, at a dose level of 0.75-1.00 rag, plasma renin activity decreased 
by 30%. Changes in other neurohormones were comparable to day 1. C 
dose-dependenhy reduced mean arterial pressure and systemic resistance 
by 10% and 18%, rasp. Pulmonary wedge and dght atrial pressure fell by 
38% and 39"/=, rasp. Cardiac pump function improved with a maximal 20% 
inorease in cardiac index. Despite a concomitant 12=/o reduction in heart rate, 
both stroke volume and stroke work increased by 32% and 31%, rasp. Mean 
pulmonary artery pressure decreased by 21%. Thus, C significantly modu- 
lates sympathetic activation already at a low dose, accompanied by changes 
in vasopressin and ANF, and, at the high dose, in the renin-angiotansin sys- 
tem. These effects lead to a reduction in systemic vascular resistance and 
heart rate, and to an improvement inca:dies pump function and left and dght 
ventdcular filling pressures, already at the lowest dose level. It is concluded 
that selective DA~ agonists such as carmokirele may be a useful addition to 
heart failure treatment through their neurohormona! modulating effects. 
~ Aldosterene in Syndromes of  Untreated 
Congestive Heart Failure 
lnder S. Anand, Y. Chandrashekhar, Roberto Ferrad, Philip Poota-Wlison, 
Peter Herds. VA Medical Center, Minneapolis, MN; National Heart & Lung 
Institute, London, UK 
Serum aldosterone is elevated in some patients with congestive heart failure 
(CHF) but its role in the pathogenesis of CHF is unclear, Aldostemne causes 
sodium retention, stimulates fibrous tissue proliferation in the heart after 
myocardial infarction and may, therefore, influence the natural history of 
heart failure. Aldosterone levels are also known to be significantly altered 
by drugs used in the treatment of CHR In view of this, we moesured and 
correlated serum aldosterone levels with hemodynamios, plasma hormones 
[norepinephrine, plasma renin activity (PRA) & ANF], total body water (TBW), 
total body exchangeable sodium (TBNa) and effective renal plasma flow 
(ERPF) In untreated patients with different syndromes of CHF: Low output 
heart failure due to systolic dysfunction (untreated ilated cerdlomyopathy, n 
= 7) & diastolic dysfunction (untreated constrictive pericarditis, n = 15), and 
high output failure (chronic or pulmonale, n = 9). Aldosterene was markedly 
irmreased in patients with untreated low output systolic CHF (330 =t: 122 
pg/ml, normal 52 :t: 7 pg/ml, p = 0,02) and correlated strongly with PRA (r 
= 0.87, p < 0.01) but not with other hormones, hemodynamics, TBW, TBNa 
or ERPR In patients with low output diastolic heart failure, aldosterone was 
moderately elevated (178 ± 42 pg/ml, p = 0.003) & correlated with PRA (r = 
